---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-058279"
form_type: "8-K"
ticker: "ELDN"
cik: "0001404281"
company_name: "Eledon Pharmaceuticals, Inc."
filed_at: "2023-11-02T23:59:59+00:00"
generated_at: "2026-06-08T23:49:16.292612+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Eledon reports Phase 1b data: tegoprubart prevents rejection with eGFR >70 in kidney transplant

## Summary
- Data from 11 participants showed no graft loss or death; one mild T cell mediated rejection (Banff 1a) on day 99 treated successfully.
- Aggregate mean eGFR above 70 mL/min/1.73m2 after day 90; no hyperglycemia, new onset diabetes, tremor, or CMV infection seen.
- Phase 2 BESTOW trial comparing tegoprubart vs. tacrolimus underway; enrollment of ~120 participants expected to complete end of 2024.
- One participant completed 1-year study with eGFR of 91 at day 374 and enrolled in Phase 2 open-label extension.

## SEC filing metadata
- accession: 0000950170-23-058279
- form_type: 8-K
- ticker: ELDN
- cik: 0001404281
- company_name: Eledon Pharmaceuticals, Inc.
- filed_at: 2023-11-02T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1404281/000095017023058279/0000950170-23-058279-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1404281/000095017023058279/eldn-20231102.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-058279
- JSON: https://secwatch.observer/filing/0000950170-23-058279.json
- Plain text: https://secwatch.observer/filing/0000950170-23-058279.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.